Sonoma Pharmaceuticals Q3 revenue rises 22%

Sonoma Pharmaceuticals

10/02/2026 21:18

Overview

Healthcare product maker's fiscal Q3 revenue rose 22% yr/yr

Net loss and EBITDAS loss decreased for fiscal Q3 compared to last year

Company expanded distribution channels and strengthened leadership

Outlook

Sonoma Pharmaceuticals did not provide specific financial guidance for future quarters or fiscal year

Result Drivers

U.S. SALES GROWTH - Revenue in the U.S. surged 98% due to increased sales of over-the-counter products and distributor expansion

EUROPEAN DEMAND - European revenues rose 24% driven by increased demand for products

LATIN AMERICA DECLINE - Latin America revenues fell 38% due to timing of customer orders

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
$4.30 mln
Q3 Gross Profit
$1.60 mln
Q3 Operating Expenses
$2.30 mln


Analyst Coverage

The one available analyst rating on the shares is "strong buy"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Sonoma Pharmaceuticals Inc is $14.80, about 408.6% above its February 9 closing price of $2.91

Press Release: ID:nACSCchpCa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)